1. Home
  2. NTRA vs BAX Comparison

NTRA vs BAX Comparison

Compare NTRA & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • BAX
  • Stock Information
  • Founded
  • NTRA 2003
  • BAX 1931
  • Country
  • NTRA United States
  • BAX United States
  • Employees
  • NTRA N/A
  • BAX N/A
  • Industry
  • NTRA Medical Specialities
  • BAX Medical/Dental Instruments
  • Sector
  • NTRA Health Care
  • BAX Health Care
  • Exchange
  • NTRA Nasdaq
  • BAX Nasdaq
  • Market Cap
  • NTRA 18.4B
  • BAX 17.3B
  • IPO Year
  • NTRA 2015
  • BAX N/A
  • Fundamental
  • Price
  • NTRA $143.94
  • BAX $33.74
  • Analyst Decision
  • NTRA Strong Buy
  • BAX Buy
  • Analyst Count
  • NTRA 17
  • BAX 9
  • Target Price
  • NTRA $179.00
  • BAX $38.56
  • AVG Volume (30 Days)
  • NTRA 1.9M
  • BAX 4.1M
  • Earning Date
  • NTRA 05-08-2025
  • BAX 05-01-2025
  • Dividend Yield
  • NTRA N/A
  • BAX 2.02%
  • EPS Growth
  • NTRA N/A
  • BAX N/A
  • EPS
  • NTRA N/A
  • BAX N/A
  • Revenue
  • NTRA $1,696,911,000.00
  • BAX $10,636,000,000.00
  • Revenue This Year
  • NTRA $13.56
  • BAX $6.13
  • Revenue Next Year
  • NTRA $18.11
  • BAX $4.12
  • P/E Ratio
  • NTRA N/A
  • BAX N/A
  • Revenue Growth
  • NTRA 56.75
  • BAX 2.66
  • 52 Week Low
  • NTRA $83.13
  • BAX $28.34
  • 52 Week High
  • NTRA $183.00
  • BAX $43.99
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 41.35
  • BAX 49.25
  • Support Level
  • NTRA $146.35
  • BAX $33.00
  • Resistance Level
  • NTRA $155.64
  • BAX $33.88
  • Average True Range (ATR)
  • NTRA 6.42
  • BAX 0.77
  • MACD
  • NTRA 0.87
  • BAX -0.25
  • Stochastic Oscillator
  • NTRA 51.93
  • BAX 24.93

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About BAX Baxter International Inc.

Baxter International Inc offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Share on Social Networks: